MetaTOC stay on top of your field, easily

Outcomes among secondary prevention implantable cardioverter-defibrillator recipients aged ≥80 years at time of implant in the West of Scotland: A 7-year retrospective review

, , , ,

Scottish Medical Journal

Published online on

Abstract

Scottish Medical Journal, Volume 71, Issue 3, Page 87-91, August 2026.
Introduction and aimsGuidelines recommend secondary prevention implantable cardioverter defibrillator (SP-ICD) therapy after significant ventricular arrhythmia. However, landmark SP-ICD trials enrolled patients with mean ages of 58–65 years. No randomised ...